Larimar Therapeutics Inc (LRMR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.79 (-0.26%), Market cap $0.43B, 52-week low–high $1.79 ~ $5.95.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Financial statements, price targets, institutional (13F) holdings and related news for Larimar Therapeutics Inc are updated in real time on BlackAll Trade.
Larimar Therapeutics Inc trades at $3.79 (-0.26%). Real-time quotes and charts are available on BlackAll Trade.
Larimar Therapeutics Inc has a market cap of about $0.43B.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product ca